Hims & Hers Faces Investor Class Action, Lead Deadline

Hims & Hers Health faces a proposed securities class action after the Federal Trade Commission and state authorities sued the telehealth company on July 29, 2026, alleging it shared sensitive customer health information with advertising platforms including Meta and Snap, charged customers for prescriptions soon after intake submissions, and made subscriptions difficult to cancel. Investor complaints allege the company failed to disclose these practices and the resulting regulatory and financial risks, making earlier statements about its business materially misleading. Hims & Hers shares fell $4.32, or 14.73%, to $25 on the news. The proposed class covers investors who purchased the company’s securities from August 4, 2025, through July 29, 2026, and eligible investors have until November 2, 2026, to seek appointment as lead plaintiff; the allegations have not been proven in court.